Belvedere Trading’s Forte Biosciences FBRX Stock Holding History

Belvedere Trading’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-977	Closed	-$806K	–	519
2021 Q2	$806K	Buy	+977	New	+$880K	0.06%	69

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

OQS

Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Belvedere Trading's FBRX Position: Q3 2021 in Review

Belvedere Trading sold out of Forte Biosciences (FBRX) in Q3 2021, closing a stake of 977 shares — an estimated $806K sold.

Belvedere Trading first reported a position in FBRX in Q2 2021 and held it in 1 quarter. The position peaked at $806K in Q2 2021. 57 funds tracked by Wall St. Rank hold FBRX as of Q3 2021.

Belvedere Trading reported no remaining Forte Biosciences position as of Q3 2021 after selling out during the quarter.
Belvedere Trading sold 977 Forte Biosciences shares in Q3 2021, an estimated $806K.
Belvedere Trading first reported a position in Forte Biosciences in Q2 2021 and held it in 1 quarter.
Belvedere Trading's Forte Biosciences position peaked at $806K in Q2 2021.
57 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2021.

Based on Belvedere Trading's 13F filing for Q3 2021, filed 19 Oct 2021.